Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 4, Pages 748-755
Publisher
Springer Nature
Online
2012-01-13
DOI
10.1038/bjc.2011.587
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aurora-A Expression Is Independently Associated with Chromosomal Instability in Colorectal Cancer
- (2015) Yoshifumi Baba et al. NEOPLASIA
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression
- (2010) Chao Zhang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
- (2010) I. Astsaturov et al. Science Signaling
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy
- (2008) S. Tanaka et al. BRITISH JOURNAL OF SURGERY
- Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer
- (2008) Y Qu et al. CANCER GENE THERAPY
- Inhibition of Aurora-A suppresses epithelial–mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells
- (2008) Xiang-Bo Wan et al. CARCINOGENESIS
- Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
- (2008) Y. Nadler et al. CLINICAL CANCER RESEARCH
- Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity
- (2008) Alfred King-Yin Lam et al. HUMAN PATHOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection
- (2008) Hong-Seok Park et al. JNCI-Journal of the National Cancer Institute
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started